Contracts › 75N91025C00024
75N91025C00024: Direct to Phase Ii Sbir Concept Award for Novel Iontophoretic Drug Delivery Device for Local and Effective Treatment of Oral Cancer
Awarded to Continuity Biosciences, Llc by National Institutes of Health (NIH).
$3.0Mobligated
$3.0Mpotential value
04 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91025C00024 |
|---|---|
| Awardee | Continuity Biosciences, Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NC |
| Offers received | 16 |
| Period of performance | 05 September 2025 to 04 September 2027 |
| Potential end | 04 September 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record